Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
S. Loibl
No relevant relationships to disclose
J. Bruey
Employment or Leadership Position - bioTheranostics
G. Von Minckwitz
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche
Research Funding - GlaxoSmithKline
M. F. Press
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
C. Solbach
No relevant relationships to disclose
C. Denkert
No relevant relationships to disclose
H. Tesch
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
T. N. Fehm
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose